share_log

8-K: Current report

8-K: Current report

8-K:重大事件
美股SEC公告 ·  06/26 12:54

Moomoo AI 已提取核心訊息

On June 25, 2024, eFFECTOR Therapeutics, Inc., a biotechnology company, reported a significant financial event. The company received a notice from Oxford Finance LLC indicating that eFFECTOR Therapeutics has defaulted on certain obligations under a Loan and Security Agreement dated March 19, 2021. The notice specified that the defaults were due to a Material Adverse Change and Insolvency, as outlined in the agreement's sections 8.3 and 8.5. As a result, all obligations under the agreement have become immediately due and payable, and will accrue interest at the default rate. Oxford Finance LLC reserves all rights to enforce the agreement's terms. This development was disclosed in eFFECTOR Therapeutics' filing with the SEC and is a matter of concern for investors and stakeholders of the company.
On June 25, 2024, eFFECTOR Therapeutics, Inc., a biotechnology company, reported a significant financial event. The company received a notice from Oxford Finance LLC indicating that eFFECTOR Therapeutics has defaulted on certain obligations under a Loan and Security Agreement dated March 19, 2021. The notice specified that the defaults were due to a Material Adverse Change and Insolvency, as outlined in the agreement's sections 8.3 and 8.5. As a result, all obligations under the agreement have become immediately due and payable, and will accrue interest at the default rate. Oxford Finance LLC reserves all rights to enforce the agreement's terms. This development was disclosed in eFFECTOR Therapeutics' filing with the SEC and is a matter of concern for investors and stakeholders of the company.
2024年6月25日,生物技術公司eFFECTOR Therapeutics, Inc.報告了一項重大財務事件。該公司收到了Oxford Finance LLC的通知,稱eFFECTOR Therapeutics違約了2021年3月19日的貸款和安全協議的某些義務。通知指明,違約是因爲協議8.3和8.5節所規定的重大不利變化和破產。因此,協議下的所有義務立即到期支付,並按默認利率計息。 Oxford Finance LLC保留所有權利以執行協議條款。這一事件披露在eFFECTOR Therapeutics向美國證券交易委員會的備案中,對公司的投資者和利益相關者構成了關注點。
2024年6月25日,生物技術公司eFFECTOR Therapeutics, Inc.報告了一項重大財務事件。該公司收到了Oxford Finance LLC的通知,稱eFFECTOR Therapeutics違約了2021年3月19日的貸款和安全協議的某些義務。通知指明,違約是因爲協議8.3和8.5節所規定的重大不利變化和破產。因此,協議下的所有義務立即到期支付,並按默認利率計息。 Oxford Finance LLC保留所有權利以執行協議條款。這一事件披露在eFFECTOR Therapeutics向美國證券交易委員會的備案中,對公司的投資者和利益相關者構成了關注點。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息